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Ethnopharmacological relevance: Chinese medicine formula (CMF) has a long history 2 
of clinical use in the treatment of various diseases under the guidance of traditional 3 
Chinese medicine (TCM) theory. The application of CMF can be divided into three 4 
levels, crude extracts, homologous compounds mixture, and specific compounds. 5 
However, the modern scientific connotation of the CMF theory has not been clarified.  6 
Aim of the review: To critically evaluate the research strategy for the investigation of 7 
compound-based CMF (CCMF). 8 
Materials and methods: The related information was collected from the scientific 9 
databases, including CNKI, Elsevier, ScienceDirect, PubMed, SpringerLink, Web of 10 
Science, and Wiley Online. 11 
Results: The research design including discovery, screening, optimization, 12 
pharmacodynamics models, and target research techniques including the targets for 13 
compatibility compounds were evaluated. Essentially it has been evaluated that the in 14 
vitro multicellular three-dimensional culture or organoid model has been proposed for 15 
the optimization model for compatibility research of CCMF. Based on these, the 16 
traditional compatibility theory of CMF, such as Monarch-Minister-Assistant-Guide 17 
(Jun-Chen-Zuo-Shi in Chinese), can probably be elucidated by the CCMF research. 18 
Conclusions: CCMF has the clear advantage of providing the exact composition and 19 
controllable quality of modern medicines, in addition to having the characteristics of 20 
multi-ingredients and multi-targets synergistic effects of TCM. However, CCMF is still 21 
associated with challenges which need to be addressed for its future use.  22 
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1. Introduction 23 
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As a long-standing science and culture, Chinese medicine formula (CMF) has a 1 
long history of clinical use in the treatment of various diseases for thousands of years, 2 
and has contributed to the prosperity and civilization of the China and the surrounding 3 
countries including Japan and Korea. 4 
In recent years, acceptance of CMF has gradually increased due to its clinical 5 
effect (Liu et al., 2015; Zhu et al., 2018). The proper compatibility of CMF requires 6 
strict guidance of traditional Chinese medicine (TCM) theory instead of the use of 7 
simply aggregated medicinal plants or compounds. “Monarch-Minister-Assistant-8 
Guide” (Jun-Chen-Zuo-Shi in Chinese) is one of the most typical and important theories, 9 
which vividly defines the different roles of the constituents in CMF. In this theory, 10 
“Mornarch drug” stands for an essential ingredient in a prescription and its leading 11 
curative role is aimed at the cause or the main syndrome of a disease. “Minister drug” 12 
stands for the ingredient which can strengthen the curative effect of the monarch drug. 13 
“Assistant drug” mainly refers to the ingredient which can cooperate with the monarch 14 
and minister drugs and inhibit their possible side effects or toxicities. “Guiding drug” 15 
mainly refers to the ingredient which can guide other constitutents to the pathogenic 16 
sites. However, the modern scientific connotation of this theory needs to be further 17 
explored and explained.  18 
As outlined above, CMF refers to a systemic constitution of Chinese medicines 19 
under the guidance of TCM theory for specific types of diseases. The earliest form of 20 
CMF is the compatibility of crude extracts, such as Xiao-Chaihu Dcoction composed 21 
of pieces of Chaihu  (Bupleurum chinense DC.), Banxia (Pinellia ternate (Thunb.) 22 
Breit.), Renshen (Panax ginseng C. A. Mey.), Gancao (Glycyrrhiza uralensis Fisch.), 23 
Huangqin (Scutellaria baicalensis Georgi), Shengjiang (Zingiber officinale Rosc.), and 24 
Dazhao (Ziziphus jujuba Mill.), which was recorded in the book of Shanghan-Zabing-25 
Lun written by Zhongjing Zhang 1800 year ago. Even now, the crude extracts remain 26 
the most common method of CMF application due to its several advantages, including 27 
definite and long-term proven effect (China Pharmacopoeia Committee, 2015; Liu, et 28 
al., 2015; Zhu et al., 2013; Zhu et al., 2018), relatively easier obtainment, simpler 29 
processing and lower cost than chemical agents that cannot be obtained by complete 30 
synthesis. However, the unclear chemical composition (active, ineffective and toxic 31 
ingredients), unverified functional targets, and indistinct molecular mechanisms hinder 32 
the extensive use of CMF globally. To overcome the defects of crude extracts, such as 33 
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the quality control, safety and inconvenient storage, further research of CMF needs to 1 
be undertaken.  2 
Zhang and Wang (2005) proposed the concept of homologous compounds 3 
mixture-based CMF (HCMF), also known as component-based CMF, such as total 4 
saponins from Huangqi (Astragalus membranaceus (Fisch.) Bge.), which propelled the 5 
CMF research to a new level (). HCMF refers to the partially identified homologous 6 
compounds mixture derived from Chinese medicine under the compatibility principles 7 
of TCM theory (Zhang et al., 2015). Although HCMF has relatively controllable quality, 8 
safety and effectiveness, such as approved Qishen-Yiqi-Diwan, Shouwu-Danshen-9 
Diwan, Zhigan-qin Capsule, and Sanye-Tangzhi Tablet, there still exists unascertained 10 
chemical constituents, and unclear targets or mechanisms, which result in the obstacles 11 
for successful illustration of the scientific connotation of the compatibility theory at the 12 
molecular level.  13 
Recently, the emerging technology of protein structure elucidation and target 14 
validation methods have helped to further push the pharmacological research of CMF, 15 
especially its new form which is composed of specific compounds with clear targets 16 
and mechanisms (Wang et al., 2008; Zhang et al., 2010). In view of this, we presented 17 
the viewpoint of the promising compound-based Chinese medicine formula (CCMF). 18 
This refers to a mixture composed of specific natural compounds derived from Chinese 19 
medicines or chemical drugs, under the principles of prescription compatibility of TCM 20 
theory. CCMF not only possesses the probable advantages of enhanced efficacy and 21 
reduced toxicity in traditional Chinese medicine formula (TCMF), but also has the 22 
improved safety, reliable therapeutic effects and clear chemical composition-based 23 
stable quality. Furthermore, the therapeutic target and mechanism are most likely to be 24 
clarified at the molecular level (Wang et al., 2008; Zhang et al., 2010), and the scientific 25 
connotation may be truly revealed for the compatibility theory, hence leading to the 26 
modernization of research of TCM. Although TCMF and HCMF also exhibit the 27 
probable synergism and attenuation effects similar to CCMF, their effective 28 
constituents are yet to be identified and mechanism of action needs to be elucidated 29 
(Table 1). 30 
 31 
 32 
Table 1 Comparison among TCMF and HCMF and CCMF 33 
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 TCMF HCMF CCMF 
Effect Synergism and attenuation 
Effective 
constituent 
Unclear Partially clear Completely clear 
Inactive 
substance 
Inclusion Inclusion Exclusion 




Animal and cellular 
levels 





No Difficult Yes 
 1 
2. Discovery of CCMF 2 
CCMF can be obtained from the following five main sources: classic prescriptions, 3 
classic Chinese medicine pair, single Chinese medicine, HCMF, and synergistic active 4 
compounds. 5 
2.1. Classic Prescriptions 6 
Classic prescriptions have shown good clinical effect (Liu et al., 2015; Zhu et al., 7 
2013; Zhu et al., 2018). These provide abundance of compounds with potential activity 8 
that can be used to comprise CCMF, such as Four-Gentlemen Decoction (Si-Jun-Zi 9 
Decoction in Chinese) with the effect of improving digestive system function, Si-Wu 10 
Decoction with the effect of improving erythropoiesis, Liuwei-Dihuang Pill 11 
traditionally used as a tonic to improve fatigue, lower back pain, menstrual symptoms 12 
and night sweats, Jingui-Shenqi Pill used as a warming enery tonic and used to treat 13 
various health conditions such as poor circulation, oedema, heart failuire and 14 
osteoporosis. The information of chemical constituents of TCMF can be obtained from 15 
the constituent analysis and related databases. Furthermore, the initial basic 16 
composition of CCMF can be obtained from high content screening of these compounds 17 
according to the original therapeutic activities of TCMF.  18 
Similar to the classic prescriptions, Chinese patent medicines approved by the 19 
Chinse Food and Drug Administration (CFDA) for their clinical application with 20 
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satisfactory effect is another source of CCMF. Chinese patent medicine is the novel 1 
Chinese medicine formulation developed through the modern pharmaceutical 2 
technology under the TCM principle of syndrome differentiation and treatment, and 3 
thus diagnosis and treatment is based on the analysis of the illness and the patient’s 4 
condition. The advantages of Chinese patent medicine are convenient use, rapid effect, 5 
and reduced side effects. For example, Shexiang-Baoxin Pill (SXBXP, China 6 
Pharmacopoeia Committee, 2015), consisting of Shexiang (Moschus berezovskii 7 
Flerov.), Chansu (Bufo  bufo  gargarizans  cantor), Renshen (Panax ginseng C. A. 8 
Mey.), Suhexiang (Liquidambar  orientalis  Mill.), Niuhuang (Bos  taurus  domesticus  9 
Gmelin), Rougui (Cinnamomum  cassia  Presl) and Bingpian (borneol), has been 10 
successfully used to treat angina pectoris and myocardial infarction. Modern 11 
pharmacological studies show that SXBXP can relax blood vessels, reduce myocardial 12 
infarction, inhibit vascular calcification and promote angiogenesis (al., 2018). We 13 
previously investigated the chemical constituents of SXBXP, 57 non-volatile 14 
components were detected by liquid chromatography with diode array detection and 15 
electrospray ionisation mass spectrometry (LC-DAD-ESI-MS) and 47 of these were 16 
identified. Among them, 20 are triterpene saponins from ginseng, 18 are bufadienolides 17 
from toad venom, 5 are cholic acids from bezoar, 1 is bilirubin from bezoar including 18 
3 other compounds (Peng et al., 2009). 49 volatile compounds were identified by gas 19 
chromatograph-mass spectrometer (GC-MS) analysis and compared with NIST05 20 
online database. These findings provide a series of compounds which can be applied in 21 
the CCMF research based on SXBXP. Arsenic sulfide, indirubin and tanshinone IIA 22 
are the main active compounds of Realgar-Indigo naturalis formula (Zhu et al., 2018), 23 
which is a famous Chinese patent medicine and is composed of realgar, indigo naturalis, 24 
Danshen (Salvia miltiorrhiza Bge.) and Taizishen (Pseudostellaria heterophylla (Miq.) 25 
Pax ex Pax et Hoffm.).  The combination use of these three compounds significantly 26 
prolongs the life span of tumor bearing mice compared to their mono- or bi-treatment, 27 
displaying probable synergistic effects (Wang et al., 2008).  28 
2.2. Classic Chinese Medicine Pair 29 
Chinese medicine pair is the fixed drug combination of two commonly used 30 
medicines and is the smallest unit of the TCM compatibility. Chinese medicine pair 31 
usually exhibits better effect or reduced toxicity compared to their use alone and is the 32 
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accumulation of clinical experience from ancient times (Yue et al., 2017; Ma et al., 1 
2019). For example, Huangqi (Astragalus membranaceus (Fisch.) Bunge) and Danggui 2 
(Angelica sinensis (Oliv.) Diels) can form a classic Chinese medicine pair, which is 3 
commonly used to significantly enhance the effect of reducing oxygen consumption 4 
and resisting fatigue (Chang et al., 2018). The main active compounds in this pair 5 
includes astragaloside, formononetin, calycosin, calycosin glycoside, and ferulic acid, 6 
etc. Zhu et al. (2019) found that the combination of ferulic acid, astragaloside and 7 
formononetin can significantly improve proliferation and aging of hematopoietic stem 8 
cells, when compared with the single drug. Another example of classic Chinese 9 
medicine pair of Fuzi (Aconitum carmichaelii Debeaux) and Gancao (Glycyrrhiza 10 
uralensis Fisch.) is from the classic treatise: Shanghan-Zabing-Lun written by 11 
Zhongjing Zhang. Hypaconitine and glycyrrhetinic acid have been identified as the 12 
main effective compounds of Fuzi and Gancao, respectively, and their combination can 13 
significantly improve the injured morphology and injury-related indexes of rat 14 
myocardial H9c2 cells caused by hypoxia and glucose deficiency at a ratio 1:1 (Wang 15 
et al., 2016). These compounds from classic Chinese medicine pair can form the basic 16 
composition of CCMF.  17 
2.3. Single Chinese Medicine 18 
A single Chinese medicine often contains complex chemical compounds, some of 19 
which display significant compatible therapeutic effects. Yimucao (Leonurus artemisia 20 
(Laur.) S. Y. Hu) has heat clearing properties that may help to regulate menstruation, 21 
promote diuresis and clear toxins from the body (China Pharmacopoeia Committee, 22 
2015) and stachydrine hydrochloride and leonurine hydrochloride are the main active 23 
constituents of Yimucao. Li et al. (2019) found that the combination of stachydrine 24 
hydrochloride (30, 45 mg/kg) and leonurine hydrochloride (15, 30 mg/kg) can 25 
significantly reduce the levels of aspartate transaminase (AST), creatine kinase (CK), 26 
CK isoenzyme-MB (CK-MB), lactate dehydrogenase (LDH), hydroxybutyrate 27 
dehydrogenase (HBDH), cardiac troponin I (cTnI), and malondialdehyde (MDA) 28 
which are serum biomarkers for myocardial injury during ischemia-reperfusion injury 29 
in rats. Furthermore the diastolic function of the heart is improved and offered 30 
protection against myocardial injury during ischemia-reperfusion, which is similar to 31 
the effects of Simvastatin tablets. Danshen (Salvia miltiorrhiza Bunge) can improve 32 
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blood circulation and disperse stasis, and it is also widely used to relieve menalgia. 1 
Traditionally, it is used to “clear heart-fire” and may also be used in mental-emotional 2 
conditions (China Pharmacopoeia Committee, 2015). The water soluble compounds 3 
present include protocatechuic aldehyde, protocatechuic acid, rosmarinic acid, caffeic 4 
acid, sodium danshensu, salvianolic acid A, and salvianolic acid B, etc. Tian et al. (2014) 5 
found that the combination of these seven compounds can significantly improve the 6 
memory impairment caused by cerebral ischemia-reperfusion injury in mice, enhance 7 
the hypoxia tolerance, increase the activity of superoxide dismutase (SOD) and catalase 8 
(CAT) in brain, and reduce the activity of acetylcholinesterase (AChE) and the level of 9 
malonaldehyde. The mechanism of memory protection involved may be related to 10 
scavenging of free radicals, apoptosis inhibition of nerve cells, and nerve regeneration 11 
in brain tissue. These active compounds can be conducive to form the novel CCMF. 12 
2.4. Homologous compounds mixture-based CMF (HCMF) 13 
Homologous compounds mixture-based CMF (HCMF), also known as 14 
components based-CMF, are composition groups with defined proportion or high 15 
homogeneity. The chemical components can be relatively recognized, and the 16 
proportion of each component is fixed. However, HCMF still contains a large number 17 
of unknown chemical constituents since it is difficult to purify the effective fractions, 18 
such as total alkaloids and total saponins. Hence it is necessary to further isolate, 19 
identify and screen the compounds contained in these preparations, which may 20 
contribute to the novel CCMF optimization.  21 
Fan et al. (2017) studied the compatibility law of anti-cancer compounds from 22 
total flavonoids of Jingjie (Schizonepeta tenuifolia Briq.) by microfluidic chip 23 
technology in a well-distributed experiment design. The results shows that the 24 
combination of luteolin, luteoloside, quercitrin, hesperidin, apigenin and genistein at a 25 
ratio of 3.06: 2.90: 2.04: 4.17: 0.12: 2.75 has better effect of apoptosis induction on 26 
lung cancer cell line A549 compared to the same dosage of total flavonoids, and the 27 
drug potency order of sequence is luteoloside, quercitrin, luteolin, apigenin, genistein 28 
and hesperidin. Cao and Deng (2016) isolated effective glycosides from the original 29 
extract of Buyang Huanwu Decocotion by acid-base precipitation and ion exchange 30 
chromatography. The mass fractions of astragaloside IV, amygdalin and paeoniflorin 31 
in the effective components are 37.98 mg/g, 5.48 mg/g and 103.6 mg/g, respectively. 32 
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The results suggest that the combination of these three compounds significantly inhibits 1 
the proliferation of rat aortic vascular smooth muscle cells (VSMC) induced by platelet 2 
derived growth factor (PDGF), and the IC50 is lower than the single compounds or the 3 
glycoside component.  4 
2.5. Synergistic Active Compounds 5 
A TCM formula usually consists of many natural products, such as herbs, animal 6 
based products and minerals, each of which contains large number of compounds. One 7 
of the biggest challenges in the modernization of TCM is to identify the active 8 
compounds that contribute to the therapeutic effects. Therefore, the identification of 9 
active compounds is necessary to elucidate the underlying mechanisms and scientific 10 
basis of TCM formula. Currently, the pharmacological effects of numerous compounds 11 
isolated from Chinese medicines and natural medicines have been studied, such as 12 
artemisinin (Bhattacharjee et al., 2018) and arsenic trioxide (Jiang et al., 2019). These 13 
compounds can comprise formula according to different key links of etiological and 14 
pathological of diseases. Ischemic stroke, also known as cerebral infarction/death, 15 
refers to ischemic necrosis or encephalomalacia caused by the ischemia and hypoxia of 16 
local brain tissue resulting from cerebral blood supply disorders. Cerebral infarction is 17 
characterized by high morbidity, disability, recurrence and mortality. The major 18 
treatment measures include thrombolysis, anti-platelet aggregation, anti-inflammatory 19 
and neuroprotection. Paeonol, a natural compound, can reduce the levels of 20 
inflammatory factors in rat brain tissue and serum after reperfusion injury of ischemic 21 
stroke, such as TNF-α, IL-1β and IL-6, which may offer a protective role by reduction 22 
of local excessive inflammation response through inhibition of the production of 23 
inflammatory factors (Yang et al., 2010). Paeonol can also significantly decrease the 24 
protein and mRNA expressions of ICAM21 and VCAM21 in ischemic brain tissue of 25 
rats, which may offer a protective role by reduction of the expression of adhesion 26 
molecules in ischemic brain tissue (Zhang et al., 2008). Paeoniflorin can significantly 27 
reduce the volume of infarction caused by middle cerebral artery occlusion and improve 28 
the MCAO-caused functional deficiencies of the nervous system in rats (Xiao et al., 29 
2005). It also alleviates the free radicals-elicited oxidative damage in rats after 30 
reperfusion injury of local ischemic stroke by improving the elimination of free radicals 31 
and increasing the expression of Nrf2 (He et al., 2014). In mice hippocampal CA1 32 
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neurons, paeoniflorin can not only inhibit Na+ current in a concentration- and 1 
frequency- dependent manner, but also control the gated properties of Na+ current, thus 2 
antagonizing intracellular Ca2+ overload (Zhang et al., 2003). Luteolin has a significant 3 
anti-inflammatory effect and can reduce LPS-induced increase of IL-6 by interfering 4 
with JNK signaling pathway and activating activator protein-1 (AP-1) in microglial 5 
cells (Saebyeol et al., 2008), and inhibiting the NF-κB, MAPK and Akt signaling 6 
pathways in activated microglia cells (Zhu et al., 2014). These compounds target 7 
different links of stroke and can be prepared by using different chemical mixtures to 8 
provide novel CCMF. 9 
A compound library is a collection of entity compounds with specific structures 10 
or functions and their related information under certain specific standards. PubChem is 11 
an open access biological information platform and database supported by the US 12 
National Institutes of Health (NIH) with the structure information of more than 30 13 
million compounds and 1 million biochemical experimental data. The compound 14 
database China Natural Products supported by Ministry of Science and Technology of 15 
China has collected more than 10,000 natural compounds. These compound library and 16 
database have provided the information for the compatibility formulation of CCMF.  17 
3. Screening approach for compatibility compound 18 
3.1. Network Pharmacology 19 
TCM network pharmacology is a rising interdisciplinary science and effectively 20 
integrates the study of TCM pharmacology with network science, systems biology, 21 
computational science and bioinformatics (Li and Zhang, 2013; Zhao et al., 2019). 22 
Currently the chemical compounds included in TCM formula can be obtained from 23 
several databases, such as TCMSP (Traditional Chinese Medicine Systems 24 
Pharmacology Database and Analysis Platform) (Ru et al., 2014), TCM 25 
Database@Taiwan (Traditional Chinese Medicine Database@Taiwan) (Chen, 2011), 26 
TCMID (Traditional Chinese Medicine Integrated Database) (Xue et al., 2013), 27 
NPACT (Naturally occurring Plant based Anticancerous Compound-activity-Target 28 
database) (Mangal et al., 2013), CancerHSP (Anticancer Herbs database of Systems 29 
Pharmacology) (Tao et al., 2015), and NPASS (Natural Product Activity and Species 30 
Source Database) (Zeng et al., 2018).  The active compounds can be selected according 31 
to the ADME-related parameters (Ru et al., 2014). 32 
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Kushen is the dry root of Sophora flavescens Aiton and Chen et al. (2017) virtually 1 
screened the anti-angiogenesis flavonoids from Kushen by molecular docking 2 
technology. A ligand database was established by collecting 126 flavonoids compounds 3 
which have been separated and identified. A receptor database is composed of 6 targets 4 
closely related to angiogenesis such as vascular endothelial growth factor α (VEGF-α), 5 
TEK receptor tyrosine kinase (TEK), vascular endothelial growth factor receptor 2 6 
(KDR), etc. The small molecule drugs which have inhibitory effect on each target are 7 
listed in the DrugBank as a control and the lowest scoring of the listed small molecule 8 
drugs to each target is set as the threshold. The Discovery Studio 2.5 (DS 2.5) software 9 
is used for molecular docking, and a total of 37 compounds with scores higher than the 10 
threshold were identified and top 10% were investigated. 11 
3.2. Biochromatography 12 
Biochromatography is a new chromatographic technique that combines bioactive 13 
materials such as receptors, carrier proteins, cell membranes and carriers as stationary 14 
phases, and utilizes the specific binding of stationary phase and compounds to screen 15 
the drug candidates. Due to the biological activity of the bioactive materials on the 16 
stationary phases, the screening compounds can be bound to the stationary phases 17 
through the hydrophobic force, van der Waals force, electrostatic action and binding 18 
sites of specific ligand, which reflects the pharmacological potential and significance 19 
of screening compounds. The biochromatography technology can eliminate the 20 
interference of inactive compounds, narrow down the research focus, and identify the 21 
structure of leading compounds when combined with HPLC and mass spectrometry.  22 
Wu et al. (2019) has established a cell membrane chromatography/ultra-high-23 
performance liquid chromatography-time of flight mass spectrometry (CMC/UPLC-24 
TOF/MS) analysis method for water extracts of Liuwei-Dihuang Decoction and 25 
completed rapid identification of 16 potential active compounds including catalpol, 26 
paeonol, oleanolic acid, etc. The isolated catalpol displays high affinity and was further 27 
proven to induce the growth of mouse osteoblasts and skull mineral area in osteoporotic 28 
zebrafish. 29 
3.3. High throughput screening 30 
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High throughput screening (HTS) technology is a powerful platform for drug 1 
screening with the characteristics of automatic operation, rapid detection, 2 
molecular/cellular level, computer analyses and use of micro-sample volumes. 3 
Marciano et al. (2019) compared the effect of small molecular compounds on MCF-7 4 
breast cancer cell lines with or without sugar in the cell medium on a 384-well 5 
microplate. Out of 7,000 compounds, 67 have been successfully identified with the 6 
effects of increased sensitivity of MCF7 to the sugar-free culture. Yuliantie et al. (2018) 7 
established a high-throughput screening model at the cellular level using secretory 8 
embryonic alkaline phosphatase (SEPA) as a reporter gene on 384-well plates, and 25 9 
positive compounds were identified from 32,000 compounds. The cytotoxicity, 10 
phosphorylation effect on STAT protein and the transcription of IFN regulatory factor 11 
(IRF) of these compounds were further investigated. 12 
3.4. Serum pharmacochemistry of Chinese medicine  13 
Serum pharmacochemistry of Chinese medicine uses modern separation and 14 
multi-dimensional combination techniques to analyze, identify or characterize the 15 
compounds in human/animal serum after administration of Chinese medicines, to 16 
reveal the correlation between these compounds and their efficacy (Wang, 2010). In 17 
serum pharmacochemistry of Chinese medicine, only the compounds distributed in 18 
serum are treated as the research object, which may significantly simplify the number 19 
of compounds to be optimized.  20 
The common analytical techniques for serum pharmacochemistry include gas 21 
chromatography, gas chromatography-mass spectrometry, high performance liquid 22 
chromatography, liquid-mass spectrometry, capillary electrochromatography, thin-23 
layer scanning, spectrophotometry, atomic absorption spectrometry, etc. HPLC method 24 
can be established for the determination of characteristic components of Chinese 25 
medicine and CMF extracts. HPLC-DAD, HPLC-DAD-MS/MS and other analytical 26 
techniques are used for classification, analysis of the structure and identification of the 27 
migrating components contained in serum. To obtain the accurate results, the 28 
fingerprints of standard substance, drug-containing serum and blank serum should be 29 
determined, analyzed and compared under the same conditions. Of particular note the 30 
serum-containing components may change with time due to the different administration 31 
methods, physical and chemical properties, absorption sites and rates of Chinese 32 
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medicine ingredients (An et al., 2013). By analyzing the serum fingerprints of the blood 1 
samples collected at different time points, the time-varying process of the whole blood 2 
composition spectrum in vivo can be found. It is necessary to establish a dynamic serum 3 
pharmacochemical profile to reflect the changes of chemical composition in vivo and 4 
the correlation between the prototype drug and metabolic components. The application 5 
of ultra-high performance liquid chromatography-mass spectrometry (UPLC-MS) can 6 
be used to identify the trace components on line (Wang et al., 2011), and 7 
pharmacodynamics can be determined (Yan et al., 2012).  8 
In our previous work, the compounds distributed in blood of SXBXP have been 9 
successfully investigated, and 17 prototype compounds and 3 metabolites were 10 
identified from rat plasma by HPLC-ESI-MS/MS (Jiang et al., 2010). 10 volatile 11 
compounds including 6 prototypes and 4 metabolites have been identified by GC/MS 12 
and NIST05 database comparison (Guo et al., 2012). Although a total of 96 compounds 13 
were identified from SXBXP in vitro, only 30 compounds were detected in blood which 14 
may simplify the difficulty of SXBXP compatibility research.  15 
There are also some limitations in the use of serum pharmacochemistry for 16 
Chinese medicine to determine its therapeutic effects. For example, Chinese medicine 17 
and formula contain complex chemical constituents, with different physical and 18 
chemical properties with different rates of absorption and distribution, therefore, it is 19 
difficult to fully determine the dynamic changes of compounds (Chen et al., 2016). The 20 
experimental animal species and their physiological and pathological conditions also 21 
have great influences on the analysis of  results, such as the obvious differences in the 22 
absorption under physiological and pathological conditions in rats (Liu et al., 2014; Shi 23 
et al., 2014). There are great differences in the pharmacokinetic characteristics of 24 
components distributed in blood from Danggui-Buxue Decoction between ischemia 25 
rats and normal rats (Shi et al., 2014). In spite of the increased difficulties in animal 26 
modeling, the application of pathological animal models has better practical 27 
significance compared with the commonly used normal animal models.  28 
4. Optimization method of compatibility compounds 29 
Due to the complex chemical constituents of traditional Chinese medicine, the 30 
research on its compatibility lacks relevant experience at the molecular level. The 31 
information on how to obtain the optimal combination of these active compounds is a 32 
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crucial step in the study of CCMF. Therefore, it is necessary to optimize the 1 
compatibility of effective compounds according to the corresponding clinical diseases 2 
and syndromes, so as to screen out the best compatibility formula. Several commonly 3 
used optimization methods are summarized below (Table 2). 4 
Table 2   Comparison of common optimization methods 5 
 Advantages Disadvantages Range of application 
Feedback 
System Control 
Efficient and rapid 
The dispersion degree of 
drug dose has great 
influence 
 Focuses on integrative 
system responses; 




The data analysis 
program is simple 
Low accuracy Low level test 
Uniform design 
The number of trials is 
greatly reduced 
Can not estimate the main 
and interaction effects in the 
anova model 
The test points are 
evenly distributed 
within the test range 
Increase-
decrease design 
Good reliability, large 
information processing 
space, and less 
experiments 
Narrow scope of application 
The effect is clear and 
there are only two 











4.1. Feedback System Control 7 
Generally, the combination use of drugs can reduce the dosage and side effects or 8 
enhance therapeutic effect compared to the single drug (Ding et al., 2017). As a novel 9 
screening technique for drug combination therapy, Feedback System Control (FSC) 10 
was firstly proposed by Wong et al. (2008). FSC is based on combination of 11 
experimental results under the guidance of differential evolution (DE) algorithm. It uses 12 
parabolic reaction surface (PRS) to define the transfer function of phenotype output and 13 
drug dose input, thereby achieving fast and precise optimization of multiple drug or 14 
16 
 
dose combinations and greatly improving the speed and efficiency. Compared to 1 
traditional methods, FSC is more efficient, which significantly reduces the efforts, cost, 2 
time and number of experimental subjects (Nowaksliwinska et al., 2016; Wong et al., 3 
2008; Silva et al., 2016). Tsutsui and the co-authors used FSC to screen out an optimal 4 
composition, consisting of three small molecule inhibitors, which enabled the single 5 
cell culture system of maintaining embryonic stem cells through single cell passage on 6 
a fibronectin-coated surface (Tsutsui et al., 2011).  Yu et al. (2013) identified the 7 
potential best combination of four flavonoids and conducted a preliminary evaluation 8 
based on the optimization of Huangqi-derived flavonoids by using an engineering 9 
approach of the FSC scheme. The optimal combination of flavonoids to maximize 10 
hypoxia response element (HRE) -mediated transcriptional activity was quickly 11 
acquired. Ding et al. has applied FSC technique to screen out the best combination of 12 
four drugs for the treatment of intestinal aphids,  so as to effectively alleviate clinical 13 
drug resistance (Ding et al., 2017). A very effective “cocktail” program with lower 14 
dosage and improved effect has been found only after 4 rounds and 32 combined tests. 15 
Therefore, FSC can undertake a significant role in screening of drug combination, 16 
which is also suitable to screen for CCMF compatibility. 17 
4.2. Orthogonal Design 18 
Orthogonal design is a method of designing multi-factor and multi-level tests 19 
through orthogonal test tables with the characteristics of uniform dispersion, uniformity 20 
and comparability. It is suitable for the compatibility optimization of TCM with limited 21 
scope and was performed at three factors and four levels for three components 22 
(polysaccharides, saponins and phenols) isolated from Banxia-Baizhu-Tianma 23 
Decoction (Xu et al., 2019). The fatty and salty diet hypertensive rats with phlegm-24 
dampness congestion symptoms were used as screening models and the parameters of 25 
glucolipid metabolism were converted into integrated efficiency according to the equal 26 
weight index. The optimal combination dosages of saponins, phenols and 27 
polysaccharides are 9.00 mg/kg, 14.50 mg/kg, and 12.95 mg/kg, respectively. 28 
4.3. Uniform design 29 
Uniform design is a method based on the principle of uniformity and can select 30 
some representative compounds and uniformly distributed points from the whole range 31 
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reflecting the major characteristics of the research object. Uniform design can reduce 1 
the scope and number of the experiments to a great extent, especially for the multi-2 
factors and multi-levels research, which is more suitable for experiments at tissue level 3 
or at whole animal level. However, it lacks the symmetrical comparability compared 4 
with the orthogonal design, and the regression analysis method should be used to 5 
process the results.  6 
Wu et al. (2016) used uniform design method to optimize the compatibility of four 7 
main compounds included in Evodia rutaecarpa decoction, namely ginsenoside-Rg1 8 
(Rg1), ginsenoside-Rb1 (Rb1), evodiamine (EV) and evodiamine (RU) for the mouse 9 
disease model of migraine. The results show that Rb1 and EV significantly increase the 10 
pharmacodynamics indicators and improve the efficacy, while Rg1 and RU contribute 11 
little to the overall formula. 12 
4.4. Other experimental designs 13 
In addition, other experimental designs like increase-decrease design and ED-NM-14 
MO trigeminy method may also be used in CCMF study. Shang et al. (2003) established 15 
this method of experiment with a baseline geometric proportion property for 16 
optimization and screening of the proportion of small formula. The advantages are the 17 
comprehensive and reliable information analysis, the large information processing 18 
space and the relatively small number of experiments. However, the increase-decrease 19 
design is used only in small CMF with clear therapeutic effects, such as formula with 20 
only two ingredients.  21 
The ED-NM-MO trigeminy method is proposed on the basis of experimental 22 
design (ED)-nonlinear modeling (NM)-multi-objective optimization (MO). It uses 23 
three related links to achieve nonlinear multi-objective optimization of prescription 24 
dose ratio. The ED-NM-MO method is suitable for the investigation of medicine 25 
properties and can be used to optimize the dosage and ratio of CMF. The compatibility 26 
composition of Danshen and Sanqi was optimized by this method, and the optimal ratio 27 
is obtained for 7 pharmacodynamic indicators and 6 pharmacodynamic indicators, 28 
respectively (Wang et al., 2006).   29 
5. Therapeutic evaluation model 30 
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Drug screening can be conducted at the levels of molecules, cells, tissues and 1 
animals. However, the use of tissues and animals are not suitable for the composition 2 
screening for CCMF owing to their low throughput. The screening at molecular level 3 
is also inappropriate for CCMF due to its characteristics of single-target. Hence, some 4 
common models for cancer research, including patient-derived cancer cell lines (PDX), 5 
patient-derived xenografts (PDC), multicellular three-dimensional (3D) cultures and 6 
organoids, are introduced. Especially, the cell 3D-culture and organoid models have 7 
tremendous potential for CCMF research. 8 
5.1. Multicellular three-Dimensional culture model 9 
In recent years, cell 3D-culture has attracted considerable attention as it can 10 
simulate physiology and pathology state better than traditional two-dimensional (2D) 11 
culture. It has a higher degree of interaction between cells and maintains more orderly 12 
tissue processing of tiny structures of organs in the body (Nath and Devi, 2016). The 13 
multicellular tumor spheroids (MCTS) is a type of models most commonly used in 14 
tumor research since its 3D structure can simulate the angiogenic tumor region 15 
composed of proliferating cells and necrotic cells (Froehlich et al., 2016). There are two 16 
construction methods for MCTS, including material assisted and mechanical device 17 
assisted construction. The low melting point agarose and Matrigel with appropriate 18 
growth factors or extracellular matrix are the commonly used materials for 3D-culture 19 
(Matte et al., 2016). The mechanical means are used to construct a physical 20 
environment conducive to cell aggregation into pellets, including suspension drop 21 
method, rotating culture system method, and so on.  22 
The formation of cell spheroids is a cell-dependent manner, although not all kinds 23 
of cells can be used in 3D-culture model. Froehlich et al. (2016) has studied the ellipsoid 24 
formations of three breast cancer cell lines MCF-7, MDA-MB-231 and SK-BR-3 under 25 
different culture conditions, including hanging drop, liquid overlay and suspension 26 
culture and 25% methocel was recommended as the most reliable and effective 27 
condition. MCF-7 cells can form spheroids under nearly all of analytical conditions. 28 
MDA-MB-231 cells form spheroids under only one scheme (liquid overlay technique, 29 
3.5% Matrigel), but SK-BR-3 cells are not spherical under any condition. Galateanu et 30 
al. (2016) used human colorectal cancer multi-cells to establish a 3D spheroid model 31 
which was applied to evaluate the effect of the clinical drug combination of folinic acid, 32 
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oxaliplatin and 5-fluorouracil. These results demonstrate the effect of carrying 1 
liposomes loaded with drugs on multicellular tumor spheres. However, the dose range 2 
needs to be confirmed through in vivo studies for combinational use of three drugs and 3 
their subsequent encapsulation into liposomes. 4 
The MCTS establishes a stereoscopic information exchange system similar to the 5 
real tumor, which plays a great role in the connection between cells and clinical trials, 6 
and enhances the early prediction of the potential of candidate drugs (Luo and Gao, 7 
2018). However, there are still some limitations for this out-of-body model. For 8 
example, not all immortal cell lines spontaneously form MCTS, which requires 9 
extensive optimization and validation,  limiting the use of this model (Juergen et al., 10 
2009). To address this problem, more complex in vitro systems are currently being 11 
evaluated, including co-culture with other cell types, such as fibroblasts, to promote the 12 
formation of MCTS and the replication of complex signals that occur in vivo (Cui et al., 13 
2017; Park J et al., 2016). On the other hand, single cell type model cannot reflect the 14 
multi-target effect characteristics of CCMF, establishment of the 3D model of multi-15 
type cells co-culture is the development direction in future. 16 
As a powerful in vitro drug evaluation model, 3D cell culture has made many 17 
gratifying achievements since its emergence. Zhang et al. (2014) found that the 18 
pathological changes in the redistribution of phosphorylated p21 activated kinase 19 
(pPAK) and other related proteins in nerve cells could only be observed under the 20 
condition of 3D culture, which could not be found in the conventional 2D cell culture 21 
model. APP and PSEN1 mutations are expressed successfully in ReNcell VM cell lines, 22 
generating FAD ReNcell lines, and then obtaining cell model that could accelerate 23 
neuronal cell differentiation to form neural network through 3D cell culture method 24 
(Choi et al., 2014; 2016). This research successfully reproduces the pathological 25 
process of Aβ deposit and drive tau protein extracellular accumulation, which provides 26 
more effective methods and techniques for the treatment of alzheimer's disease. 27 
Cell culture is an indispensable experimental technique during drug development 28 
process. 3D cell culture has become a valuable tool, which is closer to the real situations 29 
in vivo, helping to bridge the gap between the in vitro and in vivo models with reduced 30 
animal number used in the early stage of experiments and the possiblilities of error (Yu 31 
and Zhou, 2019). However, most 3D cell cultures rely on  gel substrates, and the 32 
applications are limited by their solids and opacity, as well as the inconsistencies of the 33 
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cells' exposure to environmental stimulus. Therefore, before 3D cell cultures can be 1 
widely accepted and regarded as stardard in the drug development and precision 2 
medicine related research, there are still many difficulties and obstacles which need to 3 
be tackled and solved. 4 
5.2. Organoid Model 5 
Organoid is a 3D “micro-organ model” prepared by self-organization of different 6 
types of stem cells and can mimic the structure and function of original organs 7 
(Fatehullah et al., 2016). Such in vitro culture systems include a self-renewing stem cell 8 
population that can differentiate into multiple organ-specific cell types with similar 9 
spatial tissue to the corresponding organ and be able to reproduce some of its functions 10 
thus providing highly physiologically relevant systems (Lancaster and Knoblich, 2014). 11 
In recent years, investigations on organoid have mainly focused on in vitro models of 12 
diseases and in vitro organ reconstruction, which will open up new approaches for 13 
biological research. The development and application of organoid models will be one 14 
of the hot topics in tumor and stem cell research in future (Xu et al., 2018).  15 
Organoid can be prepared using somatic cells, adult stem cells (including 16 
progenitor cells) or pluripotent stem cells. In 2009, the intestinal organ simulation 17 
technology made the technological breakthroughs. Toshiro found that adult intestinal 18 
stem cells could proliferate and spontaneously organize in vitro (Toshiro et al., 2009), 19 
hence the researchers developed a 3D culture system capable of reconstructing the 20 
appropriate environment for intestinal stem cells in vitro and differentiating from 21 
intestinal epithelial cells or single LGR5+ stem cells into organoids with self-renewal 22 
ability and maintaining the villous structure of epithelial tissues. Huch et al. optimized 23 
the condition of the mouse liver organ culture system and successfully obtained liver 24 
organs using liver duct cells derived from humans (Huch et al., 2015). This type of 25 
organ maintains the stability of the genome during long-term culture and can be 26 
converted into functional hepatocytes under conditions of in vitro culture and 27 
transplantation. After the differentiation of ESCs into the endoderm induced by activin 28 
A, Noggin and transforming growth factor-β (TGF-β) inhibitors, the expression levels 29 
of SOX2 and FOXA2 both increased, which activated the HH pathway and inhibited 30 
the FGF pathway respectively, and then the quasi-organs of the lung were obtained 31 
(Dye et al., 2015). Fong et al. (2016) co-cultured tumor cells derived from PDX model 32 
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of prostate cancer with osteoblasts, and the 3D model formed in this culture system 1 
could well maintain the proliferation activity of cells and the state of osteogenesis, 2 
which is consistent with the phenotype of bone metastasis of prostate cancer. Therefore, 3 
this organ model can be used to study the interaction between tumor cells and 4 
microenvironment including stromal cells. 5 
Compared with traditional 2D culture models, the organoid represents an 6 
innovative technique that summarizes the physiological processes of the entire 7 
organism, with such advantages as closer proximity to physiological cell composition 8 
and behavior, more stable genome, and more suitable for biological transfection and 9 
high-throughput screening. Compared with animal model, the organoid model is 10 
simpler to operate and can be used to study the mechanisms of disease occurrence and 11 
development. At present, although organoids show the ability of self-renewal and 12 
differentiation in vitro experiments, but its passage times are limited. However, the 13 
major challenge is the improvement of passage ability and the maintenance of 14 
proliferation and undifferentiation in patients. On the other hand, the effects of matrix 15 
and the vascular system have not been considered in the present organoid culture. 16 
Although organoid technology is still in its infancy, it has great potential to study a 17 
wide range of subjects, including developmental biology, disease pathology, cell 18 
biology, reproductive mechanisms, precision medicine, drug toxicity and efficacy trials. 19 
It is believed that with the continuous innovation of technology, quasi-organs as an 20 
ideal model will play an increasingly important role in human disease research.  21 
5.3. PDC and PDX Models 22 
Since the successful establishment of the HeLa cell line in 1951, a new field of 23 
cancer research has been opened, making PDC a major model for cancer research. 24 
Tumor cells need only simple culture conditions, can proliferate indefinitely in vitro, 25 
and are suitable for large-scale drug screening. However, the tumor cell lines also have 26 
serious defects in that the heterogeneity and the characteristics of tumor cells in vivo 27 
are lost during in vitro culture. The PDX model refers that the tumor tissue derived 28 
from patients is cut into small pieces and then transplanted into immune-deficient mice 29 
(Lai et al., 2017). Some tumor cell lines originated from mice can also be transplanted 30 
into mice to form tumor. Although the PDX model can maintain the heterogeneity of 31 
tumors to a large extent and has been applied to drug screening, it still faces many 32 
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problems, such as low success rate of transplantation, low screening throughput, large 1 
sample size of tumors and long experimental period (Gao and Chen, 2015; Xu et al., 2 
2018). 3 
6. Research methods of molecular targets 4 
Many publications have systematically introduced the techniques for active targets 5 
of natural products ( Zeng and Peng, 2018; Zhou and Xiao, 2018), including affinity-6 
based protein profiling (AfBPP), drug affinity responsive target stability (DARTS), 7 
cellular thermal shift assay (CETSA), stability of proteins from rates of oxidation 8 
(SPROX), target identification by chromatographic co-elution (TICC), microscale 9 
thermophoresis (MST), chemical genomics screening, chemical genomics 10 
bioinformatics prediction, differential genomics screening, differential proteomics 11 
screening, and so on. Among these, CETSA and DARTS as the validation methods can 12 
be applied to screen drug targets when combined with other assistant techniques such 13 
as quantitative mass spectrometry. We briefly introduce the frontier techniques in 14 
CCMF research below, such as CETSA, DARTS and MST. 15 
6.1. Cellular Thermal Shift Assay 16 
Cellular thermal shift assay (CETSA) was first proposed in 2013 (Daniel et al., 17 
2013). The basic principle is that when a small molecule compound binds to a protein, 18 
the thermal stability of the protein molecule is significantly improved. This kind of 19 
binding protein needs higher temperature to be aggregated and degenerated. When 20 
heated to a certain temperature, the binding protein and the unbound protein can be 21 
separated by high-speed centrifugation. The known proteins can be validated by 22 
western-blot analysis. This unique technique can directly measure drug-protein binding, 23 
and has been widely used to verify conjugation (Dai et al., 2018; Jafari et al., 2014). 24 
Currently, more than 98.3% of 558 known small molecular drug targets belong to 25 
proteins (Santos et al., 2017), and more than 3000 potential target proteins can be 26 
combined with small molecule compounds to exert pharmacological effects (Yue et al., 27 
2012). However, CETSA can only be applied to validate the known proteins of target 28 
due to the limitation of western-blot technique, and it is not suitable for high-throughput 29 
screening.   30 
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Currently, there are two kinds of high-throughput methods for drug targets 1 
screening based on improved CETSA technique. The first is to screen drugs according 2 
to the target and isolate specific compounds that bind to target proteins from candidate 3 
compounds. The novel techniques can be used to increase the throughput of screening, 4 
such as ALPHAScreen based on the interaction between donor and receptor microbeads 5 
(Jafari et al., 2014) and ligand-stabilized soluble target protein detection based on 6 
enzyme fragment chemiluminescence quantification (Martinez et al., 2018). Another is 7 
to screen targets by known drugs. Some proteins combined with a small molecule 8 
compound are obtained through high-throughput screening, which is very suitable for 9 
the target screening of CMF compounds. However, it is difficult to construct high-10 
throughput screening models based on cellular thermal shift assay (HTS-CETSA) for 11 
screening target proteins owing to the large number of candidate target proteins, their 12 
physical and chemical properties and the difficulty of biotin labeling of small molecule 13 
compounds. 14 
6.2. Drug affinity responsive target stability (DARTS) 15 
Drug affinity responsive target stability (DARTS) analysis technique was 16 
proposed by Brett et al. (2009). The basic principle is that the binding of natural small 17 
molecule compounds to target proteins can prevent proteases from digesting the target 18 
proteins. The antienzymatic stability changes of the target proteins before or after the 19 
binding is detected by electrophoresis, and then the target proteins directly bound to 20 
small molecule compounds can be analyzed by bio-mass spectrometry. The advantages 21 
of this technique are easy operation without drug modification, independence of the 22 
drugs’ action mechanism, and the technique is especially suitable for validation of 23 
protein targets with poor affinity but high abundance. For example, this technique was 24 
used to discover the binding target proteins eIF4A for resveratrol (Brett et al., 2009). 25 
However, these results may be disturbed by non-direct target proteins, especially in 26 
living cells. DARTS can also be used to identify the binding target proteins of small 27 
molecule compounds when combined with western-blot analysis (Park Y et al., 2016). 28 
Nitazoxanide, an anti-parasite drug, was proved to effectively inhibit the Wnt signaling 29 
pathway independent of adenomatous polyposis coli by targeting peptidyl arginine 30 
deiminase 2 through DARTS and western-blot analyses, suggesting its potential in the 31 
treatment of Wnt-pathway mutations in cancer patients (Qu et al., 2018). On the other 32 
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hand, the binding targets of plant extracts could also be identified by DARTS. With the 1 
combined DARTS and bio-mass spectrum analysis, the grape seed extract was found 2 
to down-regulate the whole proteins involved in translation process through the 3 
endoplasmic reticulum (ER) stress response protein of human colon cancer cells, 4 
resulting in the modification of oxidized protein, especially the amino acid residues of 5 
the protein target (Derry et al., 2014). 6 
6.3. Microscale thermophoresis 7 
Microscale Thermophoresis (MST) refers to the directional motion of molecules 8 
in the microscopic temperature gradient field. The change of biomolecular structure or 9 
conformation will cause the differences of its hydration layer, molecular weight and 10 
surface charges, which will influence the molecular distribution in the temperature 11 
gradient field. This kind of changes can be used to analyze molecular interactions and 12 
various stoichiometric parameters. MST can directly measure molecular interactions in 13 
similarly natural environments (serum and cell lysate) and in many biological solutions. 14 
MST can not only analyze the interaction between proteins, but also measure the 15 
combination of small molecular compounds and proteins. The affinity of small 16 
molecule inhibitor quercetin with kinase PKA was measured in buffer solution and 17 
human serum respectively. The affinity in serum was reduced by 400 times, indicating 18 
that the biological matrix can affect the combination of drugs with proteins, thereby 19 
interfering with the drug function (Wienken et al., 2011). Hexokinase 2 (HK2) is the 20 
rate-limiting enzyme in the first step of the glycolytic pathway, and is highly expressed 21 
in cancer cells and plays a key role in oncogenesis and metastasis. Bao et al. has verified 22 
that the target of a compound isolated from Ganoderma lucidum is HK2 protein by 23 
MST analysis (Bao et al., 2018). This compound significantly inhibits the activity of 24 
HK2, suggesting that it may be a potential drug for cancer therapy. However, MST 25 
analysis can only provide the indirect evidence of binding between small molecules and 26 
proteins through the affinity value, hence it still needs to be confirmed by other methods.  27 
7. Discussion 28 
Unclear modern scientific connotation of TCM is a major scientific issue limiting 29 
the breakthrough of TCM modernization and internationalization. The compatibility 30 
application of CMF is an important feature for TCM (Fan et al., 2014), but it is difficult 31 
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to clearly elucidate the compatibility mechanism at the levels of  decoction pieces and 1 
components. 2 
Hence, we proposed that compound-based Chinese medicine formula (CCMF) 3 
(Figure 1), which can be obtained from optimized screening of compounds from 4 
decoction pieces, components-based Chinese medicine or activity compounds with 5 
synergistic effects, can become the future direction of TCM. The complex and unclear 6 
composition of TCM is difficult to control its safety, effectiveness and quality, which 7 
limits its further clinical application. For example, TCM injections probably have 8 
shown good clinical therapeutic effects, such as the antiviral effect and improvement 9 
of myocardial ischemia. However, due to the complex constitution of unknown and 10 
ineffective materials which has been injected directly into circulation system, TCM 11 
injections have caused series of adverse drug reactions and concerns. According to the 12 
2017 Annual Report for National Adverse Drug Reaction Monitoring by CFDA, TCM 13 
injections alone accounts for 84.1% of reported TCM averse dug reactions which leads 14 
to the restriction and banning of some effective TCM injections. The CCMF research 15 





Figure 1. Key study contents involved in the research of compound-based Chinese medicine formula. 2 
In this review, Chinese patent medicine, classic prescriptions, component medicine and synergistic 3 
compounds are introduced as the common sources of compound-based Chinese medicine formula 4 
(CCMF). Serum pharmacochemistry, feedback system control (FSC) (Liu et al., 2014) and 5 
orthogonal design are the recommended optimization method for CCMF. The cellular thermal shift 6 
assay (CETSA) (Matte et al., 2016), drug affinity responsive target stability (DARTS) (Luo and 7 
Gao, 2018) and microscale thermophoresis (MST) (Cui et al., 2017) has been introduced as the 8 
screen method for drug targets. The three-dimensional (3D) cellular culture (Xu et al., 2018), 9 
organoid model (Daniel et al., 2013) and PDX model (Park J et al., 2016) has been summarized as 10 
the promising method for the efficacy evaluation.  11 
CCMF not only has the advantages of clear chemical composition and controllable 12 
quality of modern medicines, but also has the characteristics of synergistic effect of 13 
TCM. Furthermore, the compatibility mechanism of its Monarch-Minister-Assistant-14 
Guide (Jun-Chen-Zuo-Shi in Chinese) can be investigated on the basis of the 15 
therapeutic targets to elucidate the scientific connotation. For example, the Realgar-16 
Indigo naturalis formula (RIF) has been proven clinically to show good therapeutic 17 
effects on acute promyelocytic leukemia in combination with all-trans retinoic acid 18 
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(Zhu et al., 2013; 2018). To further investigate molecular mechanism, a systematic 1 
study of RIF at compounds-level was carried out by Wang et al. (2008). Arsenic sulfide, 2 
indirubin and tanshinone IIA have been identified as the main active ingredients of the 3 
formula. Arsenic sulfide alone can prolong the survival time of the acute promyelocytic 4 
leukemia mice, but the combination with indirubin and tanshinone IIA shows more 5 
signigicant therapeutic effect through the enhanced degradation of PML-RARα 6 
oncoprotein caused by arsenic sulfide which serves as “monarch drug”, increased 7 
expression of genes related to the leukocyte differentiation and maturation which 8 
caused by tanshinone IIA as “minister drug”, and decreased expression of protein 9 
promoted cell cycle by indirubin as “assistant drug”. As the “guiding drugs”, tanshinone 10 
IIA and indirubin can also increase the expression aquaglyceroporin 9 which is 11 
responsible for arsenic sulfide transportation and cell uptake. Wang et al. (2008) has 12 
clearly elucidated the synergistic molecular mechanisms of RIF, and provided an 13 
excellent example for CCMF research which should be the future direction for TCM 14 
modernization.  15 
There are three core contents in the compatibility study of CCMF, including the 16 
screening model, compatibility optimization, and targets validation. Although the 17 
complex disease environments can be better simulated in animals, they are not suitable 18 
for compatibility optimization of formula because of the limited throughput. The in 19 
vitro model of single type of cells can usually neither conform to the multifactor-caused 20 
disease progression, nor can it reflect the characteristics of multi-component and multi-21 
target synergism of CMF. The multicellular co-culture and organoid in vitro could be 22 
the ideal models for formula screening, which can not only simulate multi-factor 23 
disease environments, but also have characteristics of high screening throughput. The 24 
FSC introduced in this review also can be combined with multicellular co-culture for 25 
screening of compatibility formula of CCMF.  26 
8. Conclusions 27 
Compatibility is the advantage of Chinese medicine formula in the treatment of 28 
diseases, but its scientific connotation has not been elucidated owing to unclear active 29 
components and binding target. Although TCMF has the advantages of easier 30 
obtainment, simpler processing and lower cost, it is difficult to control its quality, safety 31 
and effectiveness due to the presence of numerous ineffective and unknown 32 
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components. HCMF still contains partially inactive and unknown substance, which is 1 
responsible for the indeterminate binding target. The quality, safety and effectiveness 2 
of CCMF can be controlled by the use of well defined compounds. Moreover, its target 3 
and mechanism of action can also be clarified further. Although there are many 4 
approaches to investigate the action targets, including CETSA, DARTS, and MST, it 5 
still lacks the high throughput screening methods for binding targets of CCMF. The 6 
combination of mass spectrometry with CETSA or DARTS has improved the 7 
throughput in a certain extent, but there still exist some defects such as isotope labeling, 8 
complicated operation, high technical requirement and cost. Multicellular culture and 9 
organoid are better vitro models for investigation of CCMF, but are currently limited 10 
in their use. There is an urgent need to establish screening models of compatibility and 11 
screening targets for CCMF. 12 
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